BiotechTube

polypill + Usual cardiovascular medications

Phase 3Completed
3 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cardiovascular Diseases

Conditions

Cardiovascular Diseases

Trial Timeline

Jun 1, 2010 → Sep 1, 2012

NCT ID
NCT01057537

About polypill + Usual cardiovascular medications

polypill + Usual cardiovascular medications is a phase 3 stage product being developed by Dr. Reddy's Laboratories for Cardiovascular Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT01057537. Target conditions include Cardiovascular Diseases.

What happened to similar drugs?

9 of 20 similar drugs in Cardiovascular Diseases were approved

Approved (9) Terminated (2) Active (9)
🔄Dulaglutide + PlaceboEli LillyPhase 3
🔄raloxifene + placeboEli LillyPhase 3
🔄Orforglipron + PlaceboEli LillyPhase 3
✅Rosuvamibe + MonorovaYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01057537Phase 3Completed

Competing Products

20 competing products in Cardiovascular Diseases

See all competitors
ProductCompanyStageHype Score
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
EvacetrapibEli LillyPhase 1
29
Orforglipron + PlaceboEli LillyPhase 3
47
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
35
Rosuvamibe + MonorovaYuhanApproved
39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
43
Rosuvamibe + MonorovaYuhanApproved
43
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
43
LexiscanAstellas PharmaPhase 2
35
mirabegron + tamsulosinAstellas PharmaPhase 1
29
TRC150094Torrent PharmaceuticalsPhase 1/2
32
Lorcaserin hydrochloride + PlaceboEisaiApproved
43
Lepodisiran Sodium + PlaceboEli LillyPhase 3
44
Retatrutide + PlaceboEli LillyPhase 3
44
Empagliflozin + PlacebosEli LillyApproved
43
Evacetrapib + PlaceboEli LillyPhase 3
32
Placebo + AZD0780AstraZenecaPhase 2
35
Risk of low dose aspirin discontinuationAstraZenecaPre-clinical
26
Midazolam + AZD5718AstraZenecaPhase 1
29